To compare the on-target activity of the more selective CDK7 inhibitor, YKL-5-124 (18) with THZ1 in MYCN-amplified NB cells, we first evaluated the extent of target engagement using a biotinylated derivative of THZ1 (bio-THZ1) (Figure 1A). This evidence concerns the gene MYCN and neuroblastoma.